Schering-Plough has launched its anesthesia-reversal drug Bridion in Sweden, with plans to inaugurate the drug in the U.K. and Germany soon. Known generically as sugammadex, the drug was rejected for U.S. sale by the FDA [1] in August, on concerns about allergic reactions. The agency said it may ask for more data on those reactions. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/fda-rejects-schering-ploughs-bridion/2008-08-01
[2] http://money.cnn.com/news/newsfeeds/articles/apwire/55e3db5105d3346cdf19167d6c401c55.htm